RxDoctor Payments Data

Margery Shane

Family · Staten Island, NYNPI 1003172784

Payments from drug & device makers

$289in general payments, 2019–2025

Across 16 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$60
  • Sumitomo Pharma America, Inc.$35
  • Merck$32
  • Exact Sciences$31
  • AstraZeneca$24
  • Otsuka America Pharmaceutical, Inc.$20
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$289 in reported general payments places this provider in the 45th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$7,150
Medicare patients
49
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$52,336
JanuviaSitagliptin Phosphate107$38,763
OzempicSemaglutide34$31,820
FarxigaDapagliflozin Propanediol85$24,384
EntrestoSacubitril/Valsartan36$17,009
RexultiBrexpiprazole22$16,287
Cinacalcet Hcl21$15,338
MounjaroTirzepatide13$13,765
XareltoRivaroxaban30$11,265
ErtapenemErtapenem Sodium17$7,815
Memantine Hcl111$7,447
LinzessLinaclotide12$6,158
JardianceEmpagliflozin19$6,124
TradjentaLinagliptin14$5,747
Incruse ElliptaUmeclidinium Bromide17$5,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$32$38,763107 claims
AstraZenecaFarxiga, Brilinta$24$28,745100 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$16,28722 claims
Lilly USA, LLCMounjaro$13$13,76513 claims
GSKIncruse Ellipta, Breo Ellipta$19$9,92628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,883 family providers in New York.

Other family in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →